Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Non-Hodgkin 15Lymphoma 15Leukemia, B-Cell 14Leukemia 14Lymphoma, Follicular 11Recurrence 9Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Mantle-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, B-Cell 4Bronchiolitis Obliterans Syndrome 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11Gemcitabine 11Carboplatin 11pirtobrutinib 10glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × ofatumumab × Clear all
NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Thomas Jefferson University

Phase 1/2 Completed
38 enrolled 17 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Thomas Jefferson University

Phase 1 Terminated
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01613300 2021-05-26

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Completed
33 enrolled
Lymphoid

Disease, Lymphoma, B-Cell

NCT00093314 2015-04-21

HuMax-CD20 in Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡